CITED2, SMARCD3 and miR132 epigenetic regulators were selected from those 200 genes that showed the greatest difference in expression levels in the case of comparing dasatinib-sensitive and dasatinib-resistant pancreatic cancer cells. This evidence concerns the gene SMARCD3 and pancreatic neoplasm.